A study of 177Lu-IM-3050 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new treatment called 177Lu-IM-3050 for people with advanced solid tumors that have not responded to or stopped working with standard treatments. The treatment targets a protein called FAP found on some cancer cells and may help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a solid tumor that has come back or not improved after at least one prior treatment
- You have tumors that can be measured on scans (or are okayed by the study doctor if not measurable in Part A)
- Your cancer shows activity on a special scan called a FAP PET/CT
- Your organs (like liver, kidneys, and bone marrow) are working well enough
- You have not had certain types of radiation or major surgery in the last month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
This trial tests a new radioactive drug, [177Lu]Lu-XT117, that seeks out and delivers radiation to solid tumors that have a specific marker called FAP. It's for people whose cancer has not responded to other treatments or who have no other options.
This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
This trial tests a new radioactive drug, Lutetium-177 FAP-75, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and deliver radiation directly to cancer cells, potentially slowing tumor growth.
This trial tests a new drug, NRT6020, that targets a protein called FAP found on many solid tumors. It aims to see if the drug is safe and how it works in people with advanced solid tumors that have not responded to other treatments.
Hear when a new Solid Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.